Celltrion teams up with another Korean biopharma in antibody discovery deal
Two Korean companies have signed a joint R&D discovery agreement, with the potential to earn in the nine-figures.
Clinical-stage biopharma Genuv has partnered up with Celltrion to discover antibodies using the former’s Shine Mouse platform, which they hope could potentially open up more R&D projects together in the future. There’s no upfront cash, but Genuv will receive milestone payments of up to $25 million if Celltrion decides to option a program into the clinic, and up to $680 million in milestones per program if its sales surpass $7.5 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.